Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10385606" target="_blank" >RIV/00216208:11110/18:10385606 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1080/08820139.2018.1480030" target="_blank" >https://doi.org/10.1080/08820139.2018.1480030</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/08820139.2018.1480030" target="_blank" >10.1080/08820139.2018.1480030</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls

Popis výsledku v původním jazyce

Background: The objective of this study was to investigate serum levels of immunosuppressive cytokines TGF beta 1 and VEGF and count of immune cells in peripheral blood in stage II and III colorectal cancer patients.Methods: Blood samples were collected from 22 colorectal patients and 25 healthy controls before the start of treatment. All patients were examined by a clinical immunologist to exclude patients with immune disorders and autoimmune diseases. TGF beta 1 and VEGF were measured by ELISA, and anti-tumor cellular immunity cells (CD4, CD8, B cells, NK cells) were measured by flow cytometry.Results: TGF beta 1 and VEGF plasma levels were significantly increased in stage II and III colorectal patients compared with control group (both p&lt;0.0001). A decrease in the cellular immunity was shown in the absolute numbers of cytotoxic T lymphocytes (CD8+ ; p=0.0240), helper T lymphocytes (CD4+ ; p=0.0019), and natural killer cells (CD16 + CD56+; p&lt;0.0001) in both stage II and stage III patients. On the contrary, B lymphocyte (CD19+) serum levels were increased in colon cancer patients (p&lt;0.0001) compared to the control group.Conclusions: Our results show peripheral blood levels of TGF beta and VEGF were significantly increased in colorectal patients and changes in cellular anticancer immunity in comparison to control group. These results will be compared with results from Immunoscore.

Název v anglickém jazyce

Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls

Popis výsledku anglicky

Background: The objective of this study was to investigate serum levels of immunosuppressive cytokines TGF beta 1 and VEGF and count of immune cells in peripheral blood in stage II and III colorectal cancer patients.Methods: Blood samples were collected from 22 colorectal patients and 25 healthy controls before the start of treatment. All patients were examined by a clinical immunologist to exclude patients with immune disorders and autoimmune diseases. TGF beta 1 and VEGF were measured by ELISA, and anti-tumor cellular immunity cells (CD4, CD8, B cells, NK cells) were measured by flow cytometry.Results: TGF beta 1 and VEGF plasma levels were significantly increased in stage II and III colorectal patients compared with control group (both p&lt;0.0001). A decrease in the cellular immunity was shown in the absolute numbers of cytotoxic T lymphocytes (CD8+ ; p=0.0240), helper T lymphocytes (CD4+ ; p=0.0019), and natural killer cells (CD16 + CD56+; p&lt;0.0001) in both stage II and stage III patients. On the contrary, B lymphocyte (CD19+) serum levels were increased in colon cancer patients (p&lt;0.0001) compared to the control group.Conclusions: Our results show peripheral blood levels of TGF beta and VEGF were significantly increased in colorectal patients and changes in cellular anticancer immunity in comparison to control group. These results will be compared with results from Immunoscore.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NV15-28188A" target="_blank" >NV15-28188A: Monitorování nádorového mikroprostředí a imunoreaktivity při posuzování prognózy a úspěšnosti léčby u pacientů s vybranými solidními nádory</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Immunological Investigations

ISSN

0882-0139

e-ISSN

—

Svazek periodika

47

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

643-653

Kód UT WoS článku

000452041600001

EID výsledku v databázi Scopus

2-s2.0-85048804245